Zentek (ZTEK) announces that its wholly-owned subsidiary, Triera Biosciences, plans to begin offering contract research organization, CRO, services for custom aptamer discovery, biosensor enablement, and machine-learning classification support to pharmaceutical, biotechnology, and diagnostics organizations in Canada, the United States, Europe, and other markets that require high-performance molecular recognition tools but do not have in-house SELEX expertise, biosensor engineering capability, or ML classification systems to develop them.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTEK:
- Zentek Wins Favorable Court Ruling, Clearing $6 Million in Claims
- Zentek announces judgement in long-standing litigation against founder
- Zentek Deepens Government and First Nations Ties Around Albany Graphite at PDAC 2026
- Zentek Launches U.S. Pilot with Quality Filters to Advance Air Filtration Push
- Zentek announces pilot evaluation program with Quality Filters